| ²é¿´: 550 | »Ø¸´: 3 | |||
wangyubobby¾èÖú¹ó±ö (СÓÐÃûÆø)
|
[½»Á÷]
¡¾½»Á÷¡¿´Ó·¢±íÂÛÎÄˮƽ¿´Ëãʲôˮƽ¡£¡£ÐÂÊÖÇóÖú ÒÑÓÐ2È˲ÎÓë
|
|
Books/Book Chapters 1. Xu, Wenfang; Zhao, Guisen; Zhang, Shijun. ¡°The Principles and Methods of New Drug Design¡± 1st Edition, China Medical Science and Technology Publishing House, Jul. 1997 2. Xu, Wenfang; Zhao, Guisen; Zhang, Shijun. ¡°The Principles and Methods of New Drug Design¡± 2d Edition, Science Publishing House, Oct. 2000 Recent Publications Lenhart, J.A.; Ling, X.; Gandhi, R.; Guo, T.L.; Gerk, P.M.; Brunzell, D.H.; Zhang, S. "Clicked" Bivalent Ligands Containing Curcumin and Cholesterol As Multifunctional Abeta Oligomerization Inhibitors: Design, Synthesis, and Biological Characterization. J. Med. Chem. 2010, 53, 6198-6209. Li, Q.; Wu, J.; Zheng, H.; Liu, K.; Guo, T.L.; Liu, Y.; Eblen, S.T.; Grant, S.; Zhang, Shijun. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. Bioorg. & Med. Chem. Lett. 2010, 20, 4526-4530. Zhang, Shijun; Yekkirala, Ajay; Tang, Ye; Portoghese, Philip S. A bivalent ligand (KMN-21) antagonist for µ/? heterodimeric opioid receptors. Bioorg & Med. Chem. Lett. 2009, 19, 6978-6980. Li, Qianbin; Al-Ayoubi, Adnan; Guo, Tailiang; Zheng, Hui; Sarkar, Aurijit; Nguyen, Tri; Eblen, Scott T.; Grant, Steven; Kellogg, Glen E.; Zhang, Shijun. Structure-activity relationship (SAR) studies of 3-(2- amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of potential substrate-specific ERK1/2 inhibitors. Bioorg & Med. Chem. Lett. 2009, 19, 6042-6046. Zhang, Shijun; Fernandez, Fernando; Zhen, Juan; Reith, Maarten E. A.; Dutta, Aloke K.. Further structural exploration of tri-substituted asymmetric pyran derivaives, (2S, 4R, 5R)-2-benzhydryl-5- benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S, 6S)-pyran derivatives: A proposed pharmacohpore model for high affinity interaction with the dopamine, serotonin, and norepinephrine transporters. J. Med. Chem. 2006, 49, 4239-4237. Zhang, Shijun; Zhen, Juan; Reith, Maarten E. A.; Dutta, Aloke K.. Design, Synthesis, and Preliminary SAR Study of 3-and 6-Sides-Chain Extended Tetrahydro-Pyran Analogues of cis- and trans-(6- benzhydryl-piperidin-3-yl)-benzylamine. Bioorg. & Med. Chem. 2006, 14, 3953- 3966. Zhang, Shijun; Zhen, Juan; Reith, Maarten E.A.; Dutta, Aloke K.. Discovery of novel tri-substituted asymmetric pyran derivatives, (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner. J. Med. Chem. 2005, 48, 4962-4971. Zhang, Shijun; Zhen, Juan; Reith, Maarten E.A.; Dutta, Aloke K.. Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters. Bioorg. & Med. Chem. 2004, 12, 6301- 6315. Dutta, Aloke K.; Venkataraman, Sylesh K.; Fei, Xiang-shu; Kolhatkar, Rohit; Zhang, Shijun; Reith,Maarten E.A.. Synthesis and biological characterization of novel hybrid 7-{[2-(4-phenylpiperazin- 1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol analogues for the dopamine D2 and D3 receptors. Bioorg. & Med. Chem. 2004, 12, 4361- 4373. Dutta, Aloke K.; Zhang, Shijun; Kohhatkar, Rohit; Reith, Maarten E.A.. Dopamine Transporter as Target for Drug Development of Cocaine Dependence Medications. Europ. J. Pharmacol. 2003, 479, 93-106. Zhang, Shijun; Reith, Maarten E.A.; Dutta, Aloke K.. Design, synthesis, and activity of novel cis- and trans-3,6-disubstituted pyran biomimetics of 3,6-disubstituted piperidine as potential ligands for the dopamine transporter. Bioorg. & Med. Chem. Lett. 2003, 13, 1591-1595. |
» ²ÂÄãϲ»¶
ÎÒ¾ÍÊÇÉêÇëÒ»¸öÃæÉÏÏîÄ¿¶øÒÑ£¬ÕâÆÀÉóÒâ¼ûÊǰ´ÕÕ½ÜÇàµÄÌõ¼þÆÀµÄ°É£¿
ÒѾÓÐ3È˻ظ´
ÓжàÉÙÈËÊǽñÌì²éϵͳ֪µÀ½á¹ûµÄ£¿
ÒѾÓÐ18È˻ظ´
¹ú×ÔÈ»ÆÀÉóÒâ¼û
ÒѾÓÐ15È˻ظ´
Ϊʲô×ÊÖúÊý¸÷´ó¸ßУ¶¼´´Ð¸ߣ¬×Ô¼ºÉêÇëÔõô¾ÍÕâôÄÑ
ÒѾÓÐ13È˻ظ´
¹ú×ÔÈ»ÃæÉϸ´ÅÌ~»¶ÓÌÖÂÛ
ÒѾÓÐ14È˻ظ´
ϵͳ²é²»µ½
ÒѾÓÐ11È˻ظ´
ÓÐûÓÐÈÔûÊÕµ½ÐÅÏ¢µÄ
ÒѾÓÐ3È˻ظ´
µ¼Ê¦Í²ۣºÎÒÔõô̯ÉÏÁËÕâô¸ö¼«Æ·Ñо¿Éú£¡
ÒѾÓÐ8È˻ظ´
»ù½ð²»ÖУ¬¹²Ãã
ÒѾÓÐ11È˻ظ´
Â鷳ר¼ÒÃÇ¿´¿´ÆÀίÃǵÄÒâ¼û£¨F¿ÚÃæÉÏ£©
ÒѾÓÐ9È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÂÛÎı»Í˻أ¬ËµÊÇÓ¢ÎÄˮƽ´ï²»µ½ÒªÇó£¬ÇóÖú¸ßÈËÄÄÀïÓнϺõÄÂÛÎÄÐ޸Ĺ«Ë¾£¿
ÒѾÓÐ9È˻ظ´
¼ÆËã»úרҵ·¢Ò»ÆªsciËãʲôˮƽ
ÒѾÓÐ12È˻ظ´
¡¾¿Î¼þ¡¿¸ßˮƽÂÛÎÄ·¢±í¼¼ÇÉ£¨ÖÐÄÏ´óѧ£©
ÒѾÓÐ97È˻ظ´
ÐÂÊÖÇóÖú£ºÈçºÎдÂÛÎÄ£¬ÈçºÎ×öʵÑé
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿Î´·¢±íµÄÂÛÎÄÄܸøÍ¬Ðп´Âð
ÒѾÓÐ12È˻ظ´
ÇóÖú£ºÃ»ÓÐÂÛÎÄ»ù´¡£¬ÈçºÎÑ¡¼ÆËã»úÀàµÄ¿ÆÑз½Ïò£¬ÈçºÎд³ö¸ßˮƽµÄÂÛÎÄ£¿
ÒѾÓÐ12È˻ظ´
¡¾ÇóÖú¡¿ÓÃmaterials studioËã¶«Î÷·¢±íÂÛÎÄʱ²Î¿¼ÎÄÏ×Ó¦¸ÃÔõôд£¿
ÒѾÓÐ3È˻ظ´
¸ßְԺУ½ÌʦÈçºÎ·¢±í¸ßˮƽµÄѧÊõÂÛÎÄÄØ£¿
ÒѾÓÐ19È˻ظ´
jiangchunyong
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
-

ר¼Ò¾Ñé: +2 - PhEPI: 2
- Ó¦Öú: 132 (¸ßÖÐÉú)
- ¹ó±ö: 2.626
- ½ð±Ò: 34018.5
- É¢½ð: 183
- ºì»¨: 44
- ɳ·¢: 21
- Ìû×Ó: 14820
- ÔÚÏß: 1602.6Сʱ
- ³æºÅ: 490643
- ×¢²á: 2008-01-03
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ҩѧ
2Â¥2011-03-27 21:41:06
wangyubobby
¾èÖú¹ó±ö (СÓÐÃûÆø)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 6.1
- Ìû×Ó: 60
- ÔÚÏß: 121.1Сʱ
- ³æºÅ: 1233422
- ×¢²á: 2011-03-15
- רҵ: ºÏ³ÉÒ©Îﻯѧ
3Â¥2011-03-27 21:45:31
jiangchunyong
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
-

ר¼Ò¾Ñé: +2 - PhEPI: 2
- Ó¦Öú: 132 (¸ßÖÐÉú)
- ¹ó±ö: 2.626
- ½ð±Ò: 34018.5
- É¢½ð: 183
- ºì»¨: 44
- ɳ·¢: 21
- Ìû×Ó: 14820
- ÔÚÏß: 1602.6Сʱ
- ³æºÅ: 490643
- ×¢²á: 2008-01-03
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ҩѧ
4Â¥2011-03-27 21:48:13









»Ø¸´´ËÂ¥
ͶƱ:
30